OpenLB
Open Library of Bioscience
Advanced Search
International journal of biological sciences
2025;21 (1): 75-94.

Artemisinin Suppressed Melanoma Recurrence and Metastasis after Radical Surgery through the KIT/PI3K/AKT Pathway.

Zhiwei Zhou, Mohd Farhan, Xingan Xing, Wenshu Zhou, Ruohong Lin, Shan Zeng, Mengfang Li, Wenhua Zheng
Author Information
  1. Zhiwei Zhou: Cancer Center and Center of Reproduction, Development & Aging, Institute of Translation Medicine, Faculty of Health Sciences, University of Macau, Taipa, Macau, China.
  2. Mohd Farhan: Cancer Center and Center of Reproduction, Development & Aging, Institute of Translation Medicine, Faculty of Health Sciences, University of Macau, Taipa, Macau, China.
  3. Xingan Xing: Cancer Center and Center of Reproduction, Development & Aging, Institute of Translation Medicine, Faculty of Health Sciences, University of Macau, Taipa, Macau, China.
  4. Wenshu Zhou: Cancer Center and Center of Reproduction, Development & Aging, Institute of Translation Medicine, Faculty of Health Sciences, University of Macau, Taipa, Macau, China.
  5. Ruohong Lin: Cancer Center and Center of Reproduction, Development & Aging, Institute of Translation Medicine, Faculty of Health Sciences, University of Macau, Taipa, Macau, China.
  6. Shan Zeng: Cancer Center and Center of Reproduction, Development & Aging, Institute of Translation Medicine, Faculty of Health Sciences, University of Macau, Taipa, Macau, China.
  7. Mengfang Li: Southern Medical University Cancer Institute, Southern Medical University, 1023 Shatai South Road, Guangzhou, Guangdong, China.
  8. Wenhua Zheng: Cancer Center and Center of Reproduction, Development & Aging, Institute of Translation Medicine, Faculty of Health Sciences, University of Macau, Taipa, Macau, China.
PMID: 39744440 DOI: 10.7150/ijbs.97341

Abstract

Cancer radical surgery is the primary treatment for melanoma, but almost all malignant melanoma patients get recurrence and Metastasis after surgery and are eventually dead. This clinical dilemma appeals to better drugs for post-surgery therapy. Artemisinin is a safe and effective antimalarial drug used in the clinic for decades. However, no information is available regarding the effect of Artemisinins on melanoma Recurrence and Metastasis after tumor excision. In the present study, we established a post-surgery tumor model on balb/c nude mice, and we found that subclinical dosages of Artemisinin significantly blocked recurrence, Metastasis, and extended survival time of mice after tumor excision. Similar results were obtained in the experiments with B16 and A375 cell lines. Further experiments confirmed that Artemisinin inhibits melanoma and after radical surgery by the c-KIT/PI3K/AKT signaling pathway. Our findings support the therapeutic potential of Artemisinin in malignant melanoma after surgery.

Keywords

AKT artemisinin c-KIT melanoma post-surgery model

References

  1. Semin Cancer Biol. 2017 Oct;46:65-83 [PMID: 28254675]
  2. Australas J Dermatol. 2020 Aug;61(3):203-209 [PMID: 32403192]
  3. Pathology. 2023 Mar;55(2):236-244 [PMID: 36641376]
  4. Clin Cancer Res. 2015 May 15;21(10):2289-96 [PMID: 25695690]
  5. Int J Oncol. 2011 Jul;39(1):279-85 [PMID: 21537836]
  6. Cancer Chemother Pharmacol. 2018 Mar;81(3):587-596 [PMID: 29392450]
  7. Leukemia. 2006 Jun;20(6):911-28 [PMID: 16642045]
  8. Invest New Drugs. 2012 Aug;30(4):1289-301 [PMID: 21547369]
  9. J Clin Oncol. 2011 Jul 20;29(21):2904-9 [PMID: 21690468]
  10. Surg Oncol Clin N Am. 2011 Jan;20(1):165-80 [PMID: 21111965]
  11. Eur J Med Chem. 2018 May 10;151:434-449 [PMID: 29649740]
  12. Clin Exp Dermatol. 2016 Jan;41(1):81-7 [PMID: 25917463]
  13. Phytother Res. 2019 May;33(5):1413-1425 [PMID: 30873702]
  14. Front Med (Lausanne). 2022 Apr 05;9:873728 [PMID: 35492361]
  15. Am J Clin Dermatol. 2019 Jun;20(3):315-323 [PMID: 30707374]
  16. Head Neck. 2013 Aug;35(8):1066-77 [PMID: 22791410]
  17. Planta Med. 2007 Apr;73(4):299-309 [PMID: 17354163]
  18. Nat Rev Dis Primers. 2015 Apr 23;1:15003 [PMID: 27188223]
  19. J Invest Dermatol. 2021 Jan;141(1):23-31 [PMID: 32268150]
  20. Nanomedicine. 2015 Nov;11(8):2041-50 [PMID: 26282380]
  21. J Clin Oncol. 2006 Sep 10;24(26):4340-6 [PMID: 16908931]
  22. Oxid Med Cell Longev. 2021 Dec 11;2021:9911537 [PMID: 34931134]
  23. Invest New Drugs. 2009 Oct;27(5):412-8 [PMID: 18956140]
  24. Nat Cancer. 2020 Feb;1(2):197-209 [PMID: 33305293]
  25. Med Res Rev. 2017 Nov;37(6):1492-1517 [PMID: 28643446]
  26. Am J Surg Pathol. 2016 Feb;40(2):181-91 [PMID: 26448190]
  27. Oncol Lett. 2020 Oct;20(4):94 [PMID: 32831913]
  28. Ann Oncol. 2019 Dec 1;30(12):1884-1901 [PMID: 31566661]
  29. Carcinogenesis. 2005 Mar;26(3):513-23 [PMID: 15358632]
  30. Curr Cancer Drug Targets. 2018;18(10):988-998 [PMID: 29692251]
  31. Arch Dermatol Res. 2012 Apr;304(3):177-84 [PMID: 22350184]
  32. Mod Pathol. 2014 Oct;27(10):1386-93 [PMID: 24603591]
  33. Cancer Res Treat. 2018 Oct;50(4):1238-1251 [PMID: 29281872]
  34. Curr Top Med Chem. 2019;19(3):205-222 [PMID: 30674260]
  35. Dis Model Mech. 2017 Sep 1;10(9):1061-1074 [PMID: 28883015]
  36. Angew Chem Int Ed Engl. 2016 Aug 22;55(35):10210-26 [PMID: 27488942]
  37. JAMA. 2011 Jun 8;305(22):2327-34 [PMID: 21642685]
  38. J Clin Oncol. 2013 Sep 10;31(26):3182-90 [PMID: 23775962]
  39. Trends Parasitol. 2019 Dec;35(12):953-963 [PMID: 31699532]
  40. Eur J Med Chem. 2020 Feb 15;188:112044 [PMID: 31945642]

MeSH Term

Animals
Artemisinins
Mice
Proto-Oncogene Proteins c-akt
Mice, Nude
Phosphatidylinositol 3-Kinases
Melanoma
Cell Line, Tumor
Mice, Inbred BALB C
Signal Transduction
Proto-Oncogene Proteins c-kit
Humans
Neoplasm Recurrence, Local
Neoplasm Metastasis

Chemicals

Artemisinins
Proto-Oncogene Proteins c-akt
Phosphatidylinositol 3-Kinases
artemisinin
Proto-Oncogene Proteins c-kit
Journal Article
Article has an altmetric score of 1

Word Cloud

Created with Highcharts 10.0.0melanomaArtemisininsurgeryrecurrencemetastasispost-surgerytumorradicalmalignantexcisionmodelmiceexperimentsCancerprimarytreatmentalmostpatientsgeteventuallydeadclinicaldilemmaappealsbetterdrugstherapysafeeffectiveantimalarialdrugusedclinicdecadesHoweverinformationavailableregardingeffectArtemisininspresentstudyestablishedbalb/cnudefoundsubclinicaldosagessignificantlyblockedextendedsurvivaltimeSimilarresultsobtainedB16A375celllinesconfirmedinhibitsc-KIT/PI3K/AKTsignalingpathwayfindingssupporttherapeuticpotentialSuppressedMelanomaRecurrenceMetastasisRadicalSurgeryKIT/PI3K/AKTPathwayAKTartemisininc-KIT

Similar Articles

Cited By

No available data.